What is HC Wainwright’s Estimate for Evolus FY2026 Earnings?

Evolus, Inc. (NASDAQ:EOLS) – Analysts at HC Wainwright dropped their FY2026 EPS estimates for shares of Evolus in a report released on Monday, March 30th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.22) for the year, down from their prior estimate of ($0.17). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Evolus’ FY2027 earnings at $0.19 EPS, FY2028 earnings at $0.64 EPS, FY2029 earnings at $1.04 EPS and FY2030 earnings at $1.41 EPS.

Several other equities research analysts have also weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Stifel Nicolaus cut their price objective on shares of Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. Wall Street Zen downgraded shares of Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, BTIG Research restated a “buy” rating and issued a $13.00 target price on shares of Evolus in a report on Wednesday, March 4th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Evolus has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Evolus Stock Performance

NASDAQ:EOLS opened at $4.03 on Wednesday. The stock has a 50-day simple moving average of $4.61 and a 200-day simple moving average of $5.85. The stock has a market cap of $262.19 million, a P/E ratio of -4.98 and a beta of 1.00. Evolus has a 1 year low of $3.86 and a 1 year high of $12.28.

Evolus (NASDAQ:EOLS) last issued its earnings results on Tuesday, March 3rd. The company reported $0.00 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The company had revenue of $90.30 million for the quarter, compared to analysts’ expectations of $89.58 million.

Insider Activity

In other news, insider David Moatazedi sold 13,669 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $4.75, for a total value of $64,927.75. Following the completion of the sale, the insider directly owned 604,700 shares of the company’s stock, valued at approximately $2,872,325. The trade was a 2.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rui Avelar sold 29,996 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $146,680.44. Following the completion of the sale, the insider directly owned 430,542 shares of the company’s stock, valued at approximately $2,105,350.38. This trade represents a 6.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 163,504 shares of company stock valued at $797,184 over the last three months. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Evolus

Several large investors have recently modified their holdings of EOLS. Rice Hall James & Associates LLC raised its position in Evolus by 17.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 1,168,886 shares of the company’s stock valued at $7,177,000 after purchasing an additional 172,846 shares during the last quarter. Divisadero Street Capital Management LP acquired a new stake in Evolus during the 3rd quarter worth $2,384,000. Frazier Life Sciences Management L.P. purchased a new position in Evolus during the 2nd quarter worth $22,431,000. Frontier Capital Management Co. LLC increased its stake in Evolus by 37.9% in the second quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company’s stock valued at $15,333,000 after purchasing an additional 457,533 shares during the period. Finally, Squarepoint Ops LLC increased its stake in Evolus by 830.2% in the second quarter. Squarepoint Ops LLC now owns 105,797 shares of the company’s stock valued at $974,000 after purchasing an additional 94,423 shares during the period. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.